Wei Wu
11PUBLICATIONS
145CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (11)
Sort by Publication Date:
|Feb 07, 2026
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.Tadashi Manabe, Hannah C Bergo, Qingtian Li
|Nov 24, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.Tadashi Manabe, Hannah C Bergo, Qingtian Li
|Jun 13, 2024
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.Sebastijan Hobor, Maise Al Bakir, Crispin T Hiley
|May 03, 2024
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.Franziska Haderk, Yu-Ting Chou, Lauren Cech
|Apr 18, 2024
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.Sanju Sinha, Rahulsimham Vegesna, Sumit Mukherjee
|Dec 04, 2023
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Deborah R Caswell, Philippe Gui, Manasi K Mayekar
Pageof 2
Frequent Collaborators
8 joint publications
Trever G Bivona
5 joint publications
Collin M Blakely
5 joint publications
D Lucas Kerr
3 joint publications
Tadashi Manabe
2 joint publications
Wei Cao
2 joint publications
Mihaela Angelova
2 joint publications
Eytan Ruppin
2 joint publications
Maise Al Bakir
2 joint publications
Whitney Tamaki
2 joint publications
Sanju Sinha
